61Cu-NODAGA前列腺特异性膜抗原显像与治疗用于前列腺癌:新型61Cu标记PET放射性示踪剂的一期试验
这项一期试验在8例18F-piflufolastat PET/CT显示PSMA阳性病灶的男性患者中评估了61Cu-PSMA I&T的安全性、剂量学、最佳显像参数和初步疗效。61Cu-PSMA I&T耐受良好,无不良事件,肾脏和泪腺受照剂量最高,全身有效剂量为0.029 mSv/MBq,给药后4小时图像显示可疑恶性病灶数最多、病灶摄取最高、本底最低;8例中4例用61Cu-PSMA I&T检出的可疑恶性病灶多于18F-piflufolastat。
要点
- 61Cu-PSMA I&T给药后4小时显像效果最佳:可疑恶性病灶数最多、病灶摄取最高、本底最低。
- 8例中4例用61Cu-PSMA I&T检出的可疑恶性病灶数多于18F-piflufolastat。
- 肾脏平均剂量0.30 mGy/MBq、泪腺平均剂量0.17 mGy/MBq为最高受照器官,全身平均有效剂量0.029 mSv/MBq。
核心结论
- 61Cu-PSMA I&T耐受良好,本一期试验未报告不良事件,剂量学可接受,并成功用于转移性前列腺癌患者的显像,给药后4小时可获得最佳图像。
研究设计与样本
- 一期试验(NCT06736054),2024年10月至2025年2月纳入8例男性参与者(平均年龄73岁±10.9[SD]),均为18F-piflufolastat PET/CT显示PSMA阳性病灶且在61Cu-PSMA I&T PET/CT前30天内完成该检查者。
关键影像表现/征象
- 给予155-318 MBq的61Cu-PSMA后,于给药后1、2、4小时行PET/CT,并采血行剂量学计算。
- 给药后4小时获得的61Cu-PSMA I&T PET/CT图像显示可疑恶性病灶数最多、病灶放射性示踪剂摄取最高、背景组织摄取最低。
- 8例参与者中4例用61Cu-PSMA I&T检出的可疑恶性病灶数多于18F-piflufolastat。
诊断标准与关键数值
- 低剂量155 MBq的61Cu-PSMA I&T即可满足显像需要。
- 肾脏平均剂量0.30 mGy/MBq、泪腺平均剂量0.17 mGy/MBq为最高受照器官,全身平均有效剂量0.029 mSv/MBq。
- 最佳显像时间为给药后4小时。
临床应用与阅片要点
- 阅片时以给药后4小时图像为准,此时可疑恶性病灶显示最多、病灶与本底对比最佳。
- 本试验未报告不良事件,但仅为8例的一期试验,原文结论为61Cu-PSMA I&T耐受良好且剂量学可接受。
局限性
- 本试验为8例男性参与者的一期试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Prostate-specific membrane antigen (PSMA)-targeted PET has revolutionized prostate cancer imaging, but the sensitivity at low prostate-specific antigen levels is lacking. Copper 61 (61Cu) is a positron emitter with favorable physical characteristics that allow for delayed imaging, which may result in improved sensitivity. Purpose To evaluate the safety, dosimetry, optimal imaging parameters, and initial efficacy of a novel 61Cu-labeled PSMA-targeting radiotracer, 61Cu-1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA)-PSMA for imaging and therapy (I&T) (hereafter, 61Cu-PSMA I&T). Materials and Methods This was a phase 1 trial of the 61Cu-labeled PSMA-targeting radiotracer, 61Cu-PSMA I&T (NCT06736054). Between October 2024 and February 2025, participants with PSMA-avid disease at fluorine 18 (18F)-piflufolastat PET/CT performed within 30 days of 61Cu-PSMA I&T PET/CT were administered 155-318 MBq of 61Cu-PSMA and then underwent PET/CT 1, 2, and 4 hours after administration and blood sampling for dosimetry. The number of suspected malignant lesions and the degree of radiotracer uptake in lesion and background tissues were compared between 61Cu-PSMA I&T and 18F-piflufolastat. Results Eight male participants (mean age, 73 years ± 10.9 [SD]) completed the trial. No adverse events were noted. A low dose of 155 MBq of 61Cu-PSMA I&T was adequate for imaging. Dosimetry calculations demonstrated that the kidney (mean, 0.30 mGy/MBq) and lacrimal glands (mean, 0.17 mGy/MBq) received the highest doses, whereas the whole-body mean effective dose was 0.029 mSv/MBq. 61Cu-PSMA I&T PET/CT images obtained 4 hours after tracer administration showed the largest number of suspected malignant lesions, the highest radiotracer uptake in the lesions, and the lowest radiotracer uptake in the background tissues. In four of the eight participants, more suspected malignant lesions were identified with 61Cu-PSMA I&T than with 18F-piflufolastat. Conclusion 61Cu-PSMA I&T was well tolerated, and no adverse events were reported in this phase 1 trial. 61Cu-PSMA I&T demonstrated acceptable dosimetry and was used for successful imaging in patients with metastatic prostate cancer. Optimal images were obtained 4 hours after tracer administration. ClinicalTrials.gov identifier no. NCT06736054. © RSNA, 2025 Supplemental material is available for this article. See also the editorial by Sinha and El Khouli in this issue.
引用
- Ulaner GA, Bassett JC, Reddy R, et al. 61Cu-NODAGA Prostate-specific Membrane Antigen Imaging and Therapy for Prostate Cancer: Phase 1 Trial of a New Class of 61Cu-labeled PET Radiotracers. Radiology. 2025. PMID: 41363974. doi:10.1148/radiol.251151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。